Panitumumab activity in metastatic colorectal cancer patients with ≥10% epidermal growth factor receptor levels

被引：0
|
作者：
Chan, E.
Neubauer, M.
Swanson, P.
Harker, W.
Burris, H.
Hecht, J.
Navale, L.
Brown, J.
Amado, R.
机构：
[1] Vanderbilt Univ Sch Med, Nashville, TN USA
[2] Kansas City Canc Ctr, Overland Pk, KS USA
[3] Hematol Oncol Associates, Port St Lucie, FL USA
[4] Utah Canc Specialists, Salt Lake City, UT USA
[5] Tennessee Oncol, Nashville, TN USA
[6] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [31] Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials
    Peeters, M.
    Van Cutsem, E.
    Berlin, J.
    Hecht, J. R.
    Ruiz, R.
    Navale, L.
    Amado, R.
    Meropol, N. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Panitumumab, a monoclonal anti-epidermal growth factor receptor antibody in colorectal cancer: Another one or the one?
    Messersmith, Wells A.
    Hidalgo, Manuel
    CLINICAL CANCER RESEARCH, 2007, 13 (16) : 4664 - 4666
  • [33] Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer
    Gibson, Tara Beers
    Ranganathan, Aarati
    Grothey, Axel
    CLINICAL COLORECTAL CANCER, 2006, 6 (01) : 29 - 31
  • [34] Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer (vol 16, pg 2205, 2010)
    Hecht, J. R.
    Mitchell, E.
    Neubauer, M. A.
    Burris, H. A., III
    Swanson, P.
    Lopez, T.
    Buchanan, G.
    Reiner, M.
    Gansert, J.
    Jordan, B.
    CLINICAL CANCER RESEARCH, 2010, 16 (10) : 2917 - 2917
  • [35] Epidermal growth factor receptor levels in human colorectal carcinoma
    Oke, OO
    Korsgen, S
    Holland, T
    Vadgama, B
    Deakin, M
    Hall, C
    Elder, JB
    GUT, 1997, 41 : A250 - A250
  • [36] The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
    Atmaca, Akin
    Werner, Dominique
    Pauligk, Claudia
    Steinmetz, Kristina
    Wirtz, Ralph
    Altmannsberger, Hans-Michael
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    BMC CANCER, 2012, 12
  • [37] The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
    Akin Atmaca
    Dominique Werner
    Claudia Pauligk
    Kristina Steinmetz
    Ralph Wirtz
    Hans-Michael Altmannsberger
    Elke Jäger
    Salah-Eddin Al-Batran
    BMC Cancer, 12
  • [38] Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
    Price, Timothy
    Ang, Agnes
    Boedigheimer, Michael
    Kim, Tae Won
    Li, Jin
    Cascinu, Stefano
    Ruff, Paul
    Suresh, Attili Satya
    Thomas, Anne
    Tjulandin, Sergei
    Peeters, Marc
    CANCER BIOLOGY & THERAPY, 2020, 21 (10) : 891 - 898
  • [39] Randomized phase II study of dual epidermal growth factor receptor inhibition with erlotinib and panitumumab with or without irinotecan as second-line therapy in patients with metastatic colorectal cancer
    Kalyan, Aparna
    Kircher, Sheetal Mehta
    Nimeiri, Halla Sayed
    Wisinski, Kari Braun
    Suh, Jason J.
    Jones, Michael
    Lakhani, Ali R.
    Rademaker, Alfred
    Mulcahy, Mary Frances
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Epidermal Growth Factor Receptor (EGFR) in primary and metastatic colorectal carcinoma
    Gupta, M
    Varma, V
    Costonis, G
    Lawson, D
    Cohen, C
    MODERN PATHOLOGY, 2005, 18 : 105A - 105A
12345